Acute Lymphoblastic Leukemia (ALL | sciencenewsnet.in

Breaking News

New study shows how salmonella tricks gut defenses to cause infection

How ecDNA Fuels Cancer by Breaking the Laws of Biology

Creating a spatial map of the sea

Much Ado About Vacuum

Researchers Uncover Achilles Heel of Antibiotic-Resistant Bacteria

HSS Appoints Daphne A. Scott, MD, Chief of Primary Sports Medicine

Study: Coronary Function Testing Improves Diagnosis of Heart Disease in Women

Multi-disciplinary teams respond to recent hurricanes to measure real time impacts of storm surge, waves

New pathways for Alzheimer’s prevention

New research sheds light on a surprising connection between COVID-19 and cancer regression

16 Nov, 2024

To wipe childhood cancer off the map, scientists must chart its genomic landscape

September 1, 2022 sarah JonasResearch Results

Scientists at St. Jude sequenced more samples of the most common childhood cancer than ever before to fully characterize the potential mutations driving disease.

Partnership with China prompts change in care for high-risk type of leukemia

January 16, 2020 sarah JonasResearch Results

Researchers from St. Jude Children’s Research Hospital and the Chinese Children’s Cancer Group led the first randomized, Phase III clinical trial comparing targeted therapies for acute lymphoblastic leukemia (ALL) driven by the Philadelphia chromosome. Results showed that the drug dasatinib provides more benefit than the standard of care, which led to changes in the way this leukemia is treated. The findings were reported today in JAMA Oncology.